Soluble endoglin antagonizes Met signaling in spindle carcinoma cells

Carcinogenesis

Volumn 36, Issue 2, 2014, Pages 212-222

  del Castillo, Gaelle ^a   Sánchez Blanco, Esther ^a   Martín Villar, Ester ^a   Valbuena Diez, Ana C ^b   Langa, Carmen ^b   Pérez Gómez, Eduardo ^c   Renart, Jaime ^a   Bernabéu, Carmelo ^b   Quintanilla, Miguel ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; ENDOGLIN; MITOGEN ACTIVATED PROTEIN KINASE; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SOLUBLE ENDOGLIN; TRANSFORMING GROWTH FACTOR BETA1; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; 7,12 DIMETHYLBENZ[A]ANTHRACENE; CELL SURFACE RECEPTOR; ENG PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; PHORBOL 13 ACETATE 12 MYRISTATE;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ARTICLE; CARCINOGENICITY; CARCINOMA CELL; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CHEMICAL CARCINOGENESIS; GENETIC TRANSFECTION; IN VITRO STUDY; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SKIN CARCINOGENESIS; SPINDLE CELL CARCINOMA; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CARCINOGENESIS; CELL MOTION; ENZYME ACTIVATION; FEMALE; GENETICS; HEK293 CELL LINE; HUMAN; METABOLISM; NUDE MOUSE; PATHOLOGY; PROGNOSIS; SARCOMA; SKIN TUMOR; TUMOR CELL CULTURE;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; ANTIGENS, CD; CARCINOGENESIS; CELL MOVEMENT; CELL PROLIFERATION; DNA, COMPLEMENTARY; ENZYME ACTIVATION; FEMALE; HEK293 CELLS; HEPATOCYTE GROWTH FACTOR; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASES; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MET; RECEPTORS, CELL SURFACE; SARCOMA; SKIN NEOPLASMS; TETRADECANOYLPHORBOL ACETATE; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA1; TUMOR CELLS, CULTURED;

EID: 84928191717     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgu240     Document Type: Article

References (44)

1. Arribas, J. et al. (2002) Protein ectodomain shedding. Chem. Rev., 102, 4627-4638.
2. Bernabeu, C. et al. (2009) The emerging role of TGF-beta superfamily coreceptors in cancer. Biochim. Biophys. Acta, 1792, 954-973.
3. ten Dijke, P. et al. (2008) Endoglin in angiogenesis and vascular diseases. Angiogenesis, 11, 79-89.
4. López-Novoa, J.M. et al. (2010) The physiological role of endoglin in the cardiovascular system. Am. J. Physiol. Heart Circ. Physiol., 299, H959-H974.
5. McAllister, K.A. et al. (1994) Genetic heterogeneity in hereditary haemorrhagic telangiectasia: possible correlation with clinical phenotype. J. Med. Genet., 31, 927-932.
6. Pérez-Gómez, E. et al. (2010) The role of the TGF-β coreceptor endoglin in cancer. ScientificWorldJournal., 10, 2367-2384.
7. Quintanilla, M. et al. (2003) Expression of the TGF-beta coreceptor endoglin in epidermal keratinocytes and its dual role in multistage mouse skin carcinogenesis. Oncogene, 22, 5976-5985.
8. Wong, V.C. et al. (2008) Identification of an invasion and tumor-suppressing gene, Endoglin (ENG), silenced by both epigenetic inactivation and allelic loss in esophageal squamous cell carcinoma. Int. J. Cancer, 123, 2816-2823.
9. Lakshman, M. et al. (2011) Endoglin suppresses human prostate cancer metastasis. Clin. Exp. Metastasis, 28, 39-53.
10. Henry, L.A. et al. (2011) Endoglin expression in breast tumor cells suppresses invasion and metastasis and correlates with improved clinical outcome. Oncogene, 30, 1046-1058.
11. Pardali, E. et al. (2011) Critical role of endoglin in tumor cell plasticity of Ewing sarcoma and melanoma. Oncogene, 30, 334-345.
12. Hawinkels, L.J. et al. (2010) Matrix metalloproteinase-14 (MT1-MMP)-mediated endoglin shedding inhibits tumor angiogenesis. Cancer Res., 70, 4141-4150.
13. Valbuena-Diez, A.C. et al. (2012) Oxysterol-induced soluble endoglin release and its involvement in hypertension. Circulation, 126, 2612-2624.
14. Venkatesha, S. et al. (2006) Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat. Med., 12, 642-649.
15. Young, B.C. et al. (2010) Pathogenesis of preeclampsia. Annu. Rev. Pathol., 5, 173-192.
16. Castonguay, R. et al. (2011) Soluble endoglin specifically binds bone morphogenetic proteins 9 and 10 via its orphan domain, inhibits blood vessel formation, and suppresses tumor growth. J. Biol. Chem., 286, 30034-30046.
17. Gregory, A.L. et al. (2014) The enigmatic role of endoglin in the placenta. Placenta, 35S, S93-S99.
18. Li, C. et al. (2000) Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer. Int. J. Cancer, 89, 122-126.
19. Takahashi, N. et al. (2001) Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin. Clin. Cancer Res., 7, 524-532.
20. Li, C. et al. (2003) Both high intratumoral microvessel density determined using CD105 antibody and elevated plasma levels of CD105 in colorectal cancer patients correlate with poor prognosis. Br. J. Cancer, 88, 1424-1431.
21. Karam, J.A. et al. (2008) Use of preoperative plasma endoglin for prediction of lymph node metastasis in patients with clinically localized prostate cancer. Clin. Cancer Res., 14, 1418-1422.
22. Pérez-Gómez, E. et al. (2007) A role for endoglin as a suppressor of malignancy during mouse skin carcinogenesis. Cancer Res., 67, 10268-10277.
23. Trusolino, L. et al. (2010) MET signalling: principles and functions in development, organ regeneration and cancer. Nat. Rev. Mol. Cell Biol., 11, 834-848.
24. Gherardi, E. et al. (2012) Targeting MET in cancer: rationale and progress. Nat. Rev. Cancer, 12, 89-103.
25. Bremner, R. et al. (1990) Genetic changes in skin tumor progression: correlation between presence of a mutant ras gene and loss of heterozygosity on mouse chromosome 7. Cell, 61, 407-417.
26. Pons, M. et al. (2005) Chromosomal instability and phenotypic plasticity during the squamous-spindle carcinoma transition: association of a specific T(14;15) with malignant progression. Oncogene, 24, 7608-7618.
27. Guerrero-Esteo, M. et al. (2002) Extracellular and cytoplasmic domains of endoglin interact with the transforming growth factor-beta receptors I and II. J. Biol. Chem., 277, 29197-29209.
28. Letamendía, A. et al. (1998) Role of endoglin in cellular responses to transforming growth factor-beta. A comparative study with betaglycan. J. Biol. Chem., 273, 33011-33019.
29. Wrobel, C.N. et al. (2004) Autocrine CSF-1R activation promotes Srcdependent disruption of mammary epithelial architecture. J. Cell Biol., 165, 263-273.
30. Pérez-Gómez, E. et al. (2005) Characterization of murine S-endoglin isoform and its effects on tumor development. Oncogene, 24, 4450-4461.
31. Quintanilla, M. et al. (1991) Comparison of ras activation during epidermal carcinogenesis in vitro and in vivo. Carcinogenesis, 12, 1875-1881.
32. Haddow, S. et al. (1991) Loss of growth control by TGF-beta occurs at a late stage of mouse skin carcinogenesis and is independent of ras gene activation. Oncogene, 6, 1465-1470.
33. Hammond, D.E. et al. (2001) Down-regulation of MET, the receptor for hepatocyte growth factor. Oncogene, 20, 2761-2770.
34. Lefebvre, J. et al. (2012) Met degradation: more than one stone to shoot a receptor down. FASEB J., 26, 1387-1399.
35. Diaz-Guerra, M. et al. (1992) Expression of simple epithelial cytokeratins in mouse epidermal keratinocytes harboring Harvey ras gene alterations. Cancer Res., 52, 680-687.
36. Santibáñez, J.F. et al. (1999) Urokinase expression and binding activity associated with the transforming growth factor beta1-induced migratory and invasive phenotype of mouse epidermal keratinocytes. J. Cell. Biochem., 74, 61-73.
37. Santibanez, J.F. et al. (2010) The TGF-beta co-receptor endoglin modulates the expression and transforming potential of H-Ras. Carcinogenesis, 31, 2145-2154.
38. Tobar, N. et al. (2014) Soluble MMP-14 produced by bone marrow-derived stromal cells sheds epithelial endoglin modulating the migratory properties of human breast cancer cells. Carcinogenesis, 35, 1770-1779.
39. Yamashita, J. et al. (1994) Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer. Cancer Res., 54, 1630-1633.
40. Taniguchi, T. et al. (1995) Serum concentrations of hepatocyte growth factor in breast cancer patients. Clin. Cancer Res., 1, 1031-1034.
41. Wong, C.E. et al. (2013) Inflammation and Hras signaling control epithelial-mesenchymal transition during skin tumor progression. Genes Dev., 27, 670-682.
42. Ponzo, M.G. et al. (2009) Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer. Proc. Natl. Acad. Sci. USA, 106, 12903-12908.
43. Gastaldi, S. et al. (2013) Met signaling regulates growth, repopulating potential and basal cell-fate commitment of mammary luminal progenitors: implications for basal-like breast cancer. Oncogene, 32, 1428-1440.
44. Gingery, A. et al. (2009) Placental ischemia and breast cancer risk after preeclampsia: tying the knot. Expert Rev. Anticancer Ther., 9, 671-681.